Wegovy/ Extensior / Poviztra
by Novo Nordisk · DCGI approved 2025–2026
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Obesity (Chronic Weight Management) |
| Manufacturer | Novo Nordisk A/S |
| DCGI status | Approved 2025–2026 |
| Price (MRP) | ₹5,660–16,400/month (post April 2026 price cut) Effective April 1, 2026, Novo Nordisk reduced Wegovy prices ~48% in response to Indian generic launches. |
| Format | Prefilled pen, five dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly) |
| Prescription | Schedule H — required |
How Wegovy compares
Wegovy is Novo Nordisk's original innovator brand of obesity-dose semaglutide (2.4 mg weekly) — the first DCGI-approved chronic weight-management semaglutide in India. Wegovy carries the SELECT cardiovascular outcomes label demonstrating 20% MACE reduction in adults with established CVD, a regulatory positioning Indian generics do not yet match. Sister brands Extensior (Emcure partnership) and Poviztra (cardiovascular indication) extend Wegovy's reach across distribution channels.
About Novo Nordisk
Novo Nordisk's STEP trial programme established the obesity-dose semaglutide evidence base, including STEP 1 (15.3% mean weight loss without diabetes), STEP 2 (T2D + obesity), and STEP 4 (continued treatment vs stopping). The SELECT trial extended this into cardiovascular outcomes, a label most Indian generics have not yet sought.
GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.